Skip to content

Ibrexafungerp

Triterpenoid Antifungal — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: brexafemme, ibrexafungerp citrate, MK-3118, SCY-078

OnpFDA approvedATC J02AX07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ibrexafungerp is an onp drug in the Triterpenoid Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Glucan Synthase Inhibitors. DrugCentral lists 3 molecular targets, including FKS, GSC1 and FKS1. Recorded indications include Candidiasis of vagina and Vulvovaginal candidiasis.

  • Approval status: onp (first approved 2021 by the FDA).
  • Drug class: Triterpenoid Antifungal.
  • Mechanism of action: Glucan Synthase Inhibitors.
  • Molecular targets: FKS, GSC1 and FKS1 (3 listed in DrugCentral).
  • Indications: Candidiasis of vagina and Vulvovaginal candidiasis.
  • ATC code: J02AX07 (Other antimycotics for systemic use).
  • Molecular formula: C44H67N5O4; molecular weight 730.05 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Candidiasis of vagina
  • Vulvovaginal candidiasis

Contraindications (1)

  • Pregnancy, function

Mechanism & targets

Mechanism of action (MoA)Glucan Synthase Inhibitors
Established pharmacologic classTriterpenoid Antifungal

Molecular targets (3)

TargetGeneActionActivity
1,3-Beta-D-glucan-UDP glucosyltransferaseFKSinhibitorIC50 8.97
Beta-1,3-glucan synthase catalytic subunit 1GSC1inhibitorIC50 8.35
1,3-Beta-D-glucan-UDP glucosyltransferaseFKS1inhibitorIC50 7.83

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2021-06-01FDA—SCYNEXIS

ATC classification

ATC codeTherapeutic hierarchy
J02AX07ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ibrexafungerp is on its molecule page.

Molecular formulaC44H67N5O4
Molecular weight730.05 g/mol
CAS number1207753-03-4
InChIKeyBODYFEUFKHPRCK-ZCZMVWJSSA-N
PubChem CID46871657
C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ibrexafungerp used for?

DrugCentral lists the following indications for Ibrexafungerp: Candidiasis of vagina and Vulvovaginal candidiasis.

How does Ibrexafungerp work?

Ibrexafungerp is classified as Glucan Synthase Inhibitors; its molecular targets in DrugCentral include FKS (inhibitor), GSC1 (inhibitor) and FKS1 (inhibitor).

When was Ibrexafungerp first approved?

Ibrexafungerp was first approved by the FDA in 2021.

What drug class does Ibrexafungerp belong to?

Ibrexafungerp is in the Triterpenoid Antifungal class.

What is the chemical formula of Ibrexafungerp?

Ibrexafungerp has the molecular formula C44H67N5O4 and a molecular weight of 730.05 g/mol.

Browse: all drugs starting with I · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2021-06-01
AgencyFDA
Targets3
Indications2
FormulaC44H67N5O4
DrugCentral ID5462
Interactive profile